H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices)(H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

H5N1流感禽流感流感病毒感染

原研机构

Resilience Government Services, Inc.

在研机构-

非在研机构

Resilience Government Services, Inc.

最高研发阶段无进展临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices) 相关的临床试验

NCT01911754

/ Completed临床3期

An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years

The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years

开始日期2013-08-01

申办/合作机构

Resilience Government Services, Inc.

[+1]

NCT01774032

/ Completed临床3期

An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Elderly Population Aged 65 Years and Older

The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese elderly population aged 65 years and older.

开始日期2013-03-01

申办/合作机构

Resilience Government Services, Inc.

NCT01382329

/ Completed临床2/3期

A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years

The purpose of this study is to obtain immunogenicity and safety data of two different dose levels of an H5N1 pandemic influenza vaccine in a healthy Japanese adult population aged 18 to 59 years.

开始日期2011-06-01

申办/合作机构

Resilience Government Services, Inc.

[+1]

100 项与 H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices) 相关的临床结果

登录后查看更多信息

100 项与 H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices) 相关的转化医学

登录后查看更多信息

100 项与 H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices) 相关的专利（医药）

登录后查看更多信息

100 项与 H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
H5N1流感	临床3期	日本	Resilience Government Services, Inc.	2011-06-01
禽流感	临床3期	新加坡	Resilience Government Services, Inc.	2009-12-01
禽流感	临床3期	澳大利亚	Resilience Government Services, Inc.	2009-12-01
禽流感	临床3期	西班牙	Resilience Government Services, Inc.	2009-12-01
禽流感	临床3期	芬兰	Resilience Government Services, Inc.	2009-12-01
流感病毒感染	临床3期	奥地利	Resilience Government Services, Inc.	2007-09-01